Myriad Genetics/$MYGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Myriad Genetics

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Ticker

$MYGN
Sector
Primary listing

Employees

2,700

Myriad Genetics Metrics

BasicAdvanced
$715M
-
-$4.33
1.93
-

What the Analysts think about Myriad Genetics

Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.

Bulls say / Bears say

Myriad surpassed Q2 revenue expectations, posting a 1% year-over-year rise to $213.1 million, and raised its full-year 2025 revenue outlook to $818–$828 million from $807–$823 million (Reuters)
Hereditary cancer testing in the Oncology segment powered 9% revenue growth and 10% volume growth year-over-year in Q2, demonstrating strong demand for the MyRisk with RiskScore solution (Reuters)
On July 31, the company secured a new $200 million credit facility, strengthening liquidity and financial flexibility to support precision oncology growth strategies (Reuters)
Q2 revenue increased by just 1% year-over-year and only 5% when excluding a $9.5 million headwind, highlighting ongoing weaker topline momentum in Myriad's core diagnostics segment (Reuters)
A $9.5 million headwind in Q2, resulting from UnitedHealthcare's decision to end GeneSight coverage and the sale of the European EndoPredict business, underscores continuing reimbursement and portfolio challenges (Reuters)
Despite raising full-year revenue guidance, Myriad left its 2025 adjusted EPS forecast unchanged at break-even ($0.02) to $0.02, reflecting limited prospects for short-term profitability improvement (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

Myriad Genetics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Myriad Genetics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MYGN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs